Advanced search
Publication Cover
Infection and Drug Resistance Volume 12, 2019 - Issue
Submit an article Journal homepage
111
Views
8
CrossRef citations to date
0
Altmetric
Original Research

Para-aminosalicylic acid increases the susceptibility to isoniazid in clinical isolates of Mycobacterium tuberculosis

Tingting Zhang1 National Clinical Laboratory on Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, People’s Republic of China;2 Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, People’s Republic of China
,
Guanglu Jiang1 National Clinical Laboratory on Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, People’s Republic of China;2 Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, People’s Republic of China
,
Shu’an Wen1 National Clinical Laboratory on Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, People’s Republic of China;2 Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, People’s Republic of China
,
Fengmin Huo1 National Clinical Laboratory on Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, People’s Republic of China;2 Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, People’s Republic of China
,
Fen Wang1 National Clinical Laboratory on Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, People’s Republic of China;2 Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, People’s Republic of China
,
Hairong Huang1 National Clinical Laboratory on Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, People’s Republic of China;2 Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, People’s Republic of ChinaCorrespondence[email protected] [email protected]
&
Yu Pang1 National Clinical Laboratory on Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, People’s Republic of China;2 Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, People’s Republic of China
 show all
Pages 825-829 | Published online: 11 Apr 2019

References

  • Rustomjee R, Diacon AH, Allen J, et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother. 2008;52(8):2831–2835. doi:10.1128/AAC.01204-0718505852
  • World Health Organization. 2018 Global tuberculosis report 2018. WHO/CDS/TB/2018.20. Geneva, Switzerland: World Health Organization.
  • Sotgiu G, Nahid P, Loddenkemper R, Abubakar I, Miravitlles M, Migliori GB. The ERS-endorsed official ATS/CDC/IDSA clinical practice guidelines on treatment of drug-susceptible tuberculosis. Eur Respir J. 2016;48(4):963–971. doi:10.1183/13993003.01356-201627587550
  • van Den Boogaard J, Kibiki GS, Kisanga ER, Boeree MJ, Aarnoutse RE. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob Agents Chemother. 2009;53(3):849–862. doi:10.1128/AAC.00749-0819075046
  • Minato Y, Thiede JM, Kordus SL, McKlveen EJ, Turman BJ, Baughn AD. Mycobacterium tuberculosis folate metabolism and the mechanistic basis for para-aminosalicylic acid susceptibility and resistance. Antimicrob Agents Chemother. 2015;59(9):5097–5106. doi:10.1128/AAC.00647-1526033719
  • Jennne JW. Partial purification and properties of the isoniazid transacetylase in human liver. Its relationship to the acetylation of p-aminosalicylic acid. J Clin Invest. 1965;44(12):1992–2002. doi:10.1172/JCI1053065851956
  • World Health Organization. 2018 Rapid communication: key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB). WHO/CDS/TB/2018.18. Geneva, Switzerland: World Health Organization.
  • Zhang L, Pang Y, Yu X, et al. Linezolid in the treatment of extensively drug-resistant tuberculosis. Infection. 2014;42(4):705–711. doi:10.1007/s15010-014-0632-224902521
  • Pang Y, Tan Y, Chen J, et al. Diversity of nontuberculous mycobacteria in eastern and southern China: a cross-sectional study. Eur Respir J. 2017;49(3). doi:10.1183/13993003.01429-2016.
  • Zou L, Liu M, Wang Y, Lu J, Pang Y. Determination of in vitro synergy between linezolid and other antimicrobial agents against Mycobacterium tuberculosis isolates. Tuberculosis (Edinb). 2015;95(6):839–842. doi:10.1016/j.tube.2015.07.00326395151
  • Gandhi NR, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet. 2010;375(9728):1830–1843. doi:10.1016/S0140-6736(10)60410-220488523
  • Lounis N, Maslo C, Truffot-Pernot C, Grosset J, Boelaert RJ. Impact of iron loading on the activity of isoniazid or ethambutol in the treatment of murine tuberculosis. Int J Tuberc Lung Dis. 2003;7(6):575–579.12797701
  • Velayati AA, Farnia P, Ibrahim TA, et al. Differences in cell wall thickness between resistant and nonresistant strains of Mycobacterium tuberculosis: using transmission electron microscopy. Chemotherapy. 2009;55:303–307. doi:10.1159/00022642519556787
  • Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis: update 2015. Int J Tuberc Lung Dis. 2015;19(11):1276–1289. doi:10.5588/ijtld.15.038926467578
  • Xu Y, Wu J, Liao S, Sun Z. Treating tuberculosis with high doses of anti-TB drugs: mechanisms and outcomes. Ann Clin Microbiol Antimicrob. 2017;16(1):67. doi:10.1186/s12941-017-0239-428974222
  • Byalik IB, Tsygankova LM, Davidenko VV, Slouch IV. Results of PAS application in complex chemotherapy of patients with destructive, ineffectively treated previously resistant pulmonary tuberculosis. Ukr Pulmonol J. 2006;1(1):56–59.
  • Mitchison D, Davies G. The chemotherapy of tuberculosis: past, present and future. Int J Tuberc Lung Dis. 2012;16(6):724–732. doi:10.5588/ijtld.12.008322613684

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.